Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30066037 | 0.81 | TLR4 (0.40) | FAAHALDH1A1CYP19A1NOS1NOS2 | |
| SCHEMBL11235896 | 0.78 | FAAH (0.39) | FAAHALDH1A1CYP19A1NOS1NOS2 | |
| SCHEMBL6531284 | 0.78 | FAAH (0.35) | FAAHALDH1A1CYP19A1NOS1NOS2 | |
| SCHEMBL9445799 | 0.77 | PRSS1 (0.33) | — | |
| SCHEMBL13236674 | 0.77 | AKR1C4 (0.40) | ALDH1A1 | |
| SCHEMBL20755048 | 0.77 | FAAH (0.33) | FAAHCYP19A1 | |
| SCHEMBL11431438 | 0.75 | ALDH1A1 (0.41) | ALDH1A1NOS2 | |
| SCHEMBL8734419 | 0.74 | FAAH (0.31) | FAAHCYP19A1NOS1NOS2 | |
| SCHEMBL6440187 | 0.74 | — | — | |
| SCHEMBL21601953 | 0.73 | FAAH (0.30) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170000808-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2017-01-05 | — | — | US | disclosed |
| US-9440995-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2016-09-13 | — | — | US | disclosed |
| US-9233985-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150191492-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2015-07-09 | — | — | US | disclosed |
| US-20120129806-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2012-05-24 | — | — | US | disclosed |
| US-6448286-B1 | PREFERENTIALLY INHIBITS OR MODULATES INDUCIBLE OVER CONSTITUTIVE ISOFORM OF NITRIC OXIDE SYNTHASE; SIDE EFFECT REDUCTION | G.D. SEARLE & CO. | 2002-09-10 | — | — | US | disclosed |
| US-6071906-A | INHIBITS OR MODULATES THE INDUCIBLE ISOFORM OF NITRIC OXIDE SYNTHASE OVER THE THE CONSTITUTIVE ISOFORMS; ANTIARTHRITIC, -DIABETIC, ISCHEMIC, THROMBOSIS AGENTS; CARDIOVASCULAR DISORDERS; TOXIC SHOCK SYNDROME; AUTOIMMUNE DISEASES | G. D. SEARLE & CO. (US) | 2000-06-06 | — | — | US | disclosed |
| US-6046211-A | TREATMENT OF ARTHRITIS OR INFLAMMATORY BOWEL DISEASE, CARDIOVASCULAR ISCHEMIA, DIABETES, HYPERALGESIA (ALLODYNIA), CEREBRAL ISCHEMIA AND OTHER CNS DISORDERS | G.D. SEARLE & CO. (US) | 2000-04-04 | — | — | US | disclosed |
| EP-0897912-A1 | Amidino derivatives useful as nitric oxide synthase inhibitors | G.D. SEARLE & CO. (US) | 1999-02-24 | — | — | EP | disclosed |
| US-5854234-A | Amidino dervatives useful as nitric oxide synthase inhibitors | G. D. SEARLE & CO. (US) | 1998-12-29 | — | — | US | disclosed |
| EP-0724570-A1 | AMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995011231-A1 | AMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G. D. SEARLE & CO. (US) | 1995-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170000808-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | FAAH 2232/4885ALDH1A1 1448/4885CYP19A1 1439/4885 |
| US-20120129806-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | FAAH 2232/4885ALDH1A1 1448/4885CYP19A1 1439/4885 |
| US-20150191492-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | FAAH 2232/4885ALDH1A1 1448/4885CYP19A1 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.